Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
PHASE1CompletedINTERVENTIONAL
Enrollment
72
Participants
Timeline
Start Date
September 30, 2005
Primary Completion Date
December 31, 2005
Study Completion Date
December 31, 2005
Conditions
Herpes GenitalisHerpes Zoster
Interventions
DRUG
ASP2151
Oral
DRUG
Placebo
Oral
Trial Locations (1)
75015
Site FR1717, Paris
All Listed Sponsors
lead
Astellas Pharma Europe Ltd.
INDUSTRY
NCT02852876 - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food | Biotech Hunter | Biotech Hunter